Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 2049-2054

  Yang, Cheng Ta ^a,c   Lin, Yu Chin ^a   Lin, Chun Liang ^a   Lu, Jessica ^a   Bu, Xuexian ^b   Tsai, Ying Huang ^c   Jia, William W G ^b,d,e  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Angiostatic proteins; Herpesvirus; Lung cancer cells

Indexed keywords

ANGIOSTATIC PROTEIN; ANGIOSTATIN; ENDOSTATIN; HERPESVIRUS VECTOR; HYBRID PROTEIN; ONCOLYTIC VIRUS; VIRUS VECTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; CULTURE MEDIUM; CYTOLYSIS; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; LUNG CANCER; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; UMBILICAL VEIN; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS RECOMBINANT AE618; VIRUS RECOMBINANT G207;

ANGIOSTATINS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENDOSTATINS; ENDOTHELIAL CELLS; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; INTERLEUKIN-12; LUNG NEOPLASMS; MICE; MICE, SCID; PROTEIN SORTING SIGNALS; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 21344463996     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bueno R: Mesothelioma clinical presentation. Chest 116(3 Suppl): 444S-445S, 1999.
2. Arriola EL, Lopez AR and Chresta CM: Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop. Oncogene 18(4): 1081-1091, 1999.
3. Heise C and Kim DH: Replication-selective adenoviruses as oncolytic agents. J Clin Invest 105(7): 847-851, 2000.
4. Kim DH: Replication-selective microbiological agents: fighting cancer with targeted germ warfare. J Clin Invest 105(7): 837-839, 2000.
5. Pawelek JM, Low KB and Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57(20): 4537-4544, 1997.
6. Heise CC, Williams AM, Xue S, Propst M and Kim DH: Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res 59(11): 2623-2628, 1999.
7. Martuza RL, Malick A, Markert JM, Ruffner KL and Coen DM: Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252(5007): 854-856, 1991.
8. Jia WW, McDermott M, Goldie J, Cynader M, Tan J and Tufaro F: Selective destruction of gliomas in immunocompetent rats by thymidine kinase-defective herpes simplex virus type 1 (see comments). J Natl Cancer Inst 86(16): 1209-1215, 1994.
9. Mineta T, Rabkin SD and Martuza RL: Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54(15): 3963-3966, 1994.
10. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A and McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells (see comments). Science 274(5286): 373-376, 1996.
11. Roizman B: The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 93(21): 11307-11312, 1996.
12. Glorioso JC, Goins WF, Fink DJ and DeLuca NA: Herpes simplex virus vectors and gene transfer to brain. Dev Biol Stand 82: 79-87, 1994.
13. Ali M, Lemoine NR and Ring CJ: The use of DNA viruses as vectors for gene therapy. Gene Ther 1(6): 367-384, 1994.
14. Geller AI and Breakefield XO: A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 241(4873): 1667-1669, 1988.
15. Martuza RL: Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 105(7): 841-846, 2000.
16. Toda M, Rabkin SD and Martuza RL: Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9(15): 2177-2185, 1998.
17. Lee JH, Federoff HJ and Schoeniger LO: G207, modified herpes simplex virus type 1, kills human pancreatic cancer cells in vitro. J Gastrointest Surg 3(2): 127-133, 1999.
18. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ and Fong Y: Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). Faseb J 13(11): 1325-1334, 1999.
19. Mineta T, Rabkin SD, Yazaki T, Hunter WD and Martuza RL: Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1(9): 938-943, 1995.
20. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F and Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7(10): 867-874, 2000.
21. Sundaresan P, Hunter WD, Martuza RL and Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 74(8): 3832-3841, 2000.
22. Hunter WD, Martuza RL, Feigenbaum F, Todo T, Mineta T, Yazaki T, Toda M, Newsome JT, Platenberg RC, Manz HJ and Rabkin SD: Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 73(8): 6319-6326, 1999.
23. Folkman J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333(26): 1757-1763, 1995.
24. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2): 277-285, 1997.
25. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2): 315-328, 1994.
26. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Cao Y, Moses M, Lane WS, Sage EH and Folkman J: Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 59: 471-482, 1994.
27. Cirri L, Donnini S, Morbidelli L, Chiarugi P, Ziche M and Ledda F: Endostatin: a promising drug for antiangiogenic therapy. Int J Biol Markers 14(4): 263-267, 1999.
28. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, Prindiville S and Franklin WA: Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6(5): 1616-1625, 2000.
29. Yuan A, Yu CJ, Chen WJ, Lin FY, Kuo SH, Luh KT and Yang PC: Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89(6): 475-483, 2000.
30. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP and Ramakrishnan S: Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res 60(8): 2190-2196, 2000.
31. Merrick WC: Mechanism and regulation of eukaryotic protein synthesis. Microbiol Rev 56(2): 291-315, 1992.
32. Chen JK, Hoshi H, McClure DB and McKeehan WL: Role of lipoproteins in growth of human adult arterial endothelial and smooth muscle cells in low lipoprotein-deficient serum. J Cell Physiol 129(2): 207-214, 1986.
33. Ranieri G and Gasparini G: Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Curr Drug Targets Immune Endocr Metabol Disord 1(3): 241-253, 2001.
34. Sridhar S and Shepherd F: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42(Suppl 1): S81-91, 2003.
35. Ponnazhagan S, Mahendra G, Kumar S, Shaw D, Stockard C, Grizzle W and Meleth S: Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy, long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 64(5): 1781-1787, 2004.
36. Chahlavi A, Todo T, Martuza R and Rabkin S: Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1(2): 162-169, 1999.
37. Cinatl JJ, Cinatl J, Michaelis M, Kabickova H, Kotchetkov R, Vogel J, Doerr H, Klingebiel T and Driever P: Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 63(7): 1508-1514, 2003.